Shijiazhuang Pharmaceutical Group Receives EDQM Certification For Vitamin B12
This article was originally published in PharmAsia News
Shijiazhuang Pharmaceutical Group has gained an on-site inspection certification for its vitamin B12 from the European Directorate for the Quality of Medicines, making it the first in China's vitamin B12 industry. The endorsement will allow China-made vitamin B12 to enter the high-end pharmaceutical field in 34 countries for manufacturing and sale. The potential market expansion and economic benefit represents major progress for local products which hitherto got little profit from the feedstuff and food industry. To avoid vicious competition in the low-end market, Shijiazhuang Pharmaceutical recently stepped up its international certification and registration efforts; it has already received EU Certificate of Suitability for six products - vitamin C, vitamin B12, caffeine, ranitidine, theophylline and amoxicillin. (Click her for more - Chinese Language)
You may also be interested in...
Dispatches from a world turned upside down include FDA expressing confidence in Chinese manufacturers – to make their GDUFA payments; projections of drug shortages for ventilator patients; and the launch of new hydroxychloroquine studies.
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.